Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer

 Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter
 of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to
                     Respond to Prior Docetaxel Treatment

At Six Months Post Launch, Almost One Third of Surveyed Urologists have
Prescribed Xtandi in Clinical Practice, According to a New Report from
BioTrends Research Group

PR Newswire

EXTON, Pa., May 6, 2013

EXTON, Pa., May 6, 2013 /PRNewswire/ --BioTrends Research Group, one of the
world's leading research and advisory firms for specialized biopharmaceutical
issues, finds that, at six months following launch of Xtandi (Astellas
Pharma/Medivation's enzalutamide), surveyed urologists and medical oncologists
prescribed Xtandi to a respective 19 percent and 24 percent of their
metastatic castrate-resistant prostate cancer (mCRPC) patients who have failed
to respond or had very rapid progression from docetaxel (Sanofi's Taxotere,
generics) treatment. In six months' time, surveyed respondents expect to
prescribe Xtandi to 35-39 percent of these mCRPC patients, making Xtandi the
patient share leader in this patient population.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The second wave of the LaunchTrends^®: Xtandi report series, fielded six
months following the launch of Xtandi in the United States, finds that 30
percent of surveyed urologists have prescribed Xtandi in clinical practice
compared with 43 percent of surveyed medical oncologists. In contrast, data
published just one month post launch of Xtandi revealed that less than 10
percent surveyed urologists had prescribed Xtandi in clinical practice (i.e.,
outside of clinical trials), compared with 39 percent of their medical
oncologist counterparts. Lack of familiarity with Xtandi and because many
eligible patients are already receiving Zytiga (Johnson & Johnson/Janssen
Biotech/Janssen Cilag's abiraterone) are key reasons cited by surveyed
respondents for not having prescribed Xtandi yet. However, the majority of
current non-prescribing urologists (61 percent) and medical oncologists (88
percent) surveyed tell us that they expect to prescribe Xtandi within the next
six months.

The findings also reveal that if Xtandi successfully secures a first-line
label extension for use in chemotherapy-naive, asymptomatic or minimally
symptomatic mCRPC, surveyed medical oncologists and urologists would prescribe
it to nearly half of their eligible patients. Surveyed respondents' estimates
of Xtandi's patient share in this patient population exceeds their current
estimates of patient share for any other currently prescribed therapy in this
setting, including Zytiga, exemplifying surveyed physicians' enthusiasm for
this agent and eagerness to use it earlier in the mCRPC treatment algorithm.

"Xtandi is experiencing rapid uptake within its FDA-approved indication for
docetaxel-pretreated mCRPC, and its inclusion on National Comprehensive Cancer
Network guidelines for use in chemotherapy-naive, asymptomatic mCRPC patients
who are not candidates for docetaxel is spurring its use in this earlier
disease setting," said Decision Resources Group Senior Director of Oncology
Rachel Webster, D.Phil. "While more than half of surveyed physicians report
decreased use of Jevtana (Sanofi's cabazitaxel) in their docetaxel pretreated
mCRPC patients, more than half of surveyed respondents currently report no
change in their use ofZytigain this setting."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please visit www.bio-trends.com. BioTrends is a
Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group
atwww.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com

SOURCE BioTrends Research Group

Website: http://www.bio-trends.com
 
Press spacebar to pause and continue. Press esc to stop.